Capsule switching of Neisseria meningitidis sequence type 7 serogroup A to serogroup X

Ji, Xiaofu; Yao, Pingping; Zhang, Le-Yi; Li, Yang; Fang, Xu; Mei, Lingling; Zhu, Shanli; Zhang, Yanjun; Zhu, Han-Ping; Veen, Stijn van der

doi:10.1016/j.jinf.2017.09.003

Cited by 15 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…65 It has also been shown this switch can occur at high frequency (6.3 × 10 −6 per bacterium per μg of DNA). 66 A MenC cc4821 hyperinvasive strain has increasingly been isolated since 2003 67 and cc4821 has also been identified among MenB isolates. Capsular switching between the two serogroups is well documented.…”

Section: Chinamentioning

confidence: 99%

Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative

Aye

Bai

Borrow

et al. 2020

Journal of Infection

View full text Add to dashboard Cite

The incidence of IMD is low and similar across the represented countries (< 0.2 cases per 10 0,0 0 0 persons per year), with the predominant serogroups of Neisseria meningitidis being B, W and Y, although serogroups A and X are present in some areas. Resistance to ciprofloxacin is also of concern, with the close monitoring of antibiotic-resistant clonal complexes (e.g., cc4821) being a priority. Meningococcal vaccination is only included in a few National Immunization Programs, but is recommended for high-risk groups, including travellers (such as pilgrims) and people with complement deficiencies or human immunodeficiency virus (HIV). Both polysaccharide and conjugate vaccines form part of recommendations. However, cost and misconceptions remain limiting factors in vaccine uptake, despite conjugate vaccines preventing the acquisition of carriage.

show abstract

Section: Chinamentioning

confidence: 99%

Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative

Aye

Bai

Borrow

et al. 2020

Journal of Infection

View full text Add to dashboard Cite

show abstract

“…The 13-valent pneumococcal conjugate vaccine PCV13 (Prevnar 13, Pfizer), collected total revenues exceeding 17.5 billion USD in 2015-2017 [12], and the market for pneumococcal vaccines is expected to increase further in the coming years. Even though pneumococcal and meningococcal diseases are preventable by the existing vaccines, variations in global serotype distributions and serotype replacement events require continuous monitoring of the vaccine serotype coverage [2,13,14]. A typical example is, again, pneumococcal vaccination that is being broadened with additional S. pneumoniae serogroups, shifting from PCV13 to the PCV15 [15] and PCV20 [16] vaccines, both of which are currently in Phase III clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Glycoconjugate vaccines: current approaches towards faster vaccine design

Micoli¹,

Bino²,

Alfini³

et al. 2019

Expert Review of Vaccines

101

View full text Add to dashboard Cite

Introduction: Over the last decades, glycoconjugate vaccines have been proven to be a successful strategy to prevent infectious diseases. Many diseases remain to be controlled, especially in developing countries, and emerging antibiotic-resistant bacteria present an alarming public-health threat. The increasing complexity of future vaccines, and the need to accelerate development processes have triggered the development of faster approaches to glycoconjugate vaccines design.Areas covered: This review provides an overview of recent progress in glycoconjugation technologies toward faster vaccine design. Expert opinion: Among the different emerging approaches, glycoengineering has the potential to combine glycan assembly and conjugation to carrier systems (such as proteins or outer membrane vesicles) in one step, resulting in a simplified manufacturing process and fewer analytical controls. Chemical and enzymatic strategies, and their automation can facilitate glycoepitope identification for vaccine design. Other approaches, such as the liposomal encapsulation of polysaccharides, potentially enable fast and easy combination of numerous antigens in the same formulation. Additional progress is envisaged in the near future, and some of these systems still need to be further validated in humans. In parallel, new strategies are needed to accelerate the vaccine development process, including the associated clinical trials, up to vaccine release onto the market.

show abstract

“…The capsular change in meningococci may have resulted in the high Serogroup X carriage in our study. In China, Ji et al [29] showed that capsule switching happens at a high frequency and occurs in an emerging sequence Type 7 Serogroup X strain. In the literature, however, there is no information on the capsular switch between MenW (a previously circulating viral serogroup in Turkey) and MenX.…”

Section: Discussionmentioning

confidence: 99%

Nasopharyngeal Meningococcal Carriage among Children and Adolescents in Turkey in 2018: An Unexpected High Serogroup X Carriage

et al. 2021

View full text Add to dashboard Cite

Meningococcal carriage studies and transmission modeling can predict IMD epidemiology and used to define invasive meningococcal disease (IMD) control strategies. In this multicenter study, we aimed to evaluate the prevalence of nasopharyngeal Neisseria meningitidis (Nm) carriage, serogroup distribution, and related risk factors in Turkey. Nasopharyngeal samples were collected from a total of 1267 children and adolescents and were tested with rt-PCR. Nm carriage was detected in 96 participants (7.5%, 95% CI 6.1–9.0), with the peak age at 13 years (12.5%). Regarding age groups, Nm carriage rate was 7% in the 0–5 age group, was 6.9%in the 6–10 age group, was 7.9% in the 11–14 age group, and was 9.3% in the 15–18 age group. There was no statistically significant difference between the groups (p > 0.05). The serogroup distribution was as follows: 25% MenX, 9.4% MenA, 9.4% MenB, 2.1% MenC, 3.1% MenW, 2.1% for MenY, and 48.9% for non-groupable. The Nm carriage rate was higher in children with previous upper respiratory tract infections and with a high number of household members, whereas it was lower in children with antibiotic use in the last month (p < 0.05 for all). In this study, MenX is the predominant carriage strain. The geographical distribution of Nm strains varies, but serogroup distribution in the same country might change in a matter of years. Adequate surveillance and/or a proper carriage study is paramount for accurate/dynamic serogroup distribution and the impact of the proposed vaccination.

show abstract

Capsule switching of Neisseria meningitidis sequence type 7 serogroup A to serogroup X

Cited by 15 publications

References 43 publications

Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative

Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative

Glycoconjugate vaccines: current approaches towards faster vaccine design

Nasopharyngeal Meningococcal Carriage among Children and Adolescents in Turkey in 2018: An Unexpected High Serogroup X Carriage

Contact Info

Product

Resources

About